Viewing Study NCT01288092

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:51 PM
Ignite Modification Date: 2026-05-23 @ 10:08 AM
Study NCT ID: NCT01288092
Status: WITHDRAWN
Last Update Posted: 2012-06-07
First Post: 2011-01-19
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
Sponsor: Novartis Pharmaceuticals
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Metastatic breast cancer View
None HER2 negative View
None HR positive View
None PI3K pathway View
None no more than 2 prior lines of chemotherapy View
None Metastatic Breast Cancer(MBC) View